Clinical efficacy and safety of intravenous ferric carboxymaltose treatment of pediatric restless legs syndrome and periodic limb movement disorder

Iron supplementation is the most commonly considered treatment option for children with restless legs syndrome (RLS) or periodic limb movement disorder (PLMD); however, there is a scarcity of evidence on the effectiveness of intravenous preparations. In this study, we evaluated the effectiveness and...

Full description

Saved in:
Bibliographic Details
Published in:Sleep medicine 2021-11, Vol.87, p.114-118
Main Authors: DelRosso, Lourdes M., Ferri, Raffaele, Chen, Maida L., Kapoor, Vidhi, Allen, Richard P., Mogavero, Maria Paola, Picchietti, Daniel L.
Format: Article
Language:English
Subjects:
Child
Children
Ferric carboxymaltose
Ferric Compounds - adverse effects
Ferritin
Humans
Iron supplementation
Maltose - analogs & derivatives
Nocturnal Myoclonus Syndrome
Periodic limb movement disorder
Restless legs syndrome
Restless Legs Syndrome - drug therapy
Retrospective Studies
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Iron supplementation is the most commonly considered treatment option for children with restless legs syndrome (RLS) or periodic limb movement disorder (PLMD); however, there is a scarcity of evidence on the effectiveness of intravenous preparations. In this study, we evaluated the effectiveness and tolerability of intravenous ferric carboxymaltose (IV FCM) on clinical symptoms and iron indices in children with RLS or PLMD. This was a single-center retrospective data analysis. Children with a diagnosis of RLS or PLMD, who underwent a single infusion of IV FCM, were included. Clinical Global Impression (CGI) Scale scores, serum ferritin, and serum iron profile at baseline and after eight weeks post infusion were obtained. Adverse effects were assessed. Thirty-nine children received IV FCM, 29 with RLS and 10 with PLMD. Pre-infusion CGI-Severity revealed moderate illness, with post-infusion CGI-Improvement between “very much improved” and “much improved”. Ferritin increased from 14.6 μg/L±7.01 to 112.4 μg/L±65.86 (p 
ISSN:1389-9457
1878-5506
DOI:10.1016/j.sleep.2021.08.030